Royal Fund Management’s Opus Genetics IRD Stock Holding History

Royal Fund Management’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	–	–	596
2020 Q1	$0	Hold	1	–	–	﹤0.01%	769
2019 Q4	$0	Hold	1	–	–	﹤0.01%	716
2019 Q3	$0	Hold	1	–	–	﹤0.01%	682
2019 Q2	$0	Buy	+1	New	+$23	﹤0.01%	680

Other funds holding IRD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Royal Fund Management's IRD Position: Q2 2020 in Review

Royal Fund Management sold out of Opus Genetics (IRD) in Q2 2020, closing a stake of 1 share.

Royal Fund Management first reported a position in IRD in Q2 2019 and held it in 4 quarters. The position peaked at $0 in Q1 2020. 14 funds tracked by Wall St. Rank hold IRD as of Q2 2020.

Royal Fund Management reported no remaining Opus Genetics position as of Q2 2020 after selling out during the quarter.
Royal Fund Management sold 1 Opus Genetics share in Q2 2020.
Royal Fund Management first reported a position in Opus Genetics in Q2 2019 and held it in 4 quarters.
Royal Fund Management's Opus Genetics position peaked at $0 in Q1 2020.
14 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.